Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Adalimumab for induction of clinical remission in moderately to severely active ulcerative ..
Tag : adalimumab
Infliximab switch to Adalimumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Background and Aims: In the 4-week GAIN clinical trial, adalimumab was efficacious ..
Adalimumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Classic-I trial induction 2006 Background & aims: Tumor necrosis factor blockade has been shown ..
Adalimumab with immunomodulator in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Combination therapy anti-TNF (in this case Adalimumab/Humira) with immunomodulator, ..
Recent Comments